Plazomicin: A New Aminoglycoside.
Plazomicin (ACHN-490) is a novel parenteral aminoglycoside developed to target multidrug-resistant Enterobacteriaceae. It has recently been approved by the Food and Drug Administration (FDA) for the management of complicated urinary tract infections and pyelonephritis caused by susceptible organisms. When compared to meropenem, plazomicin was not inferior. The adverse event profile for plazomicin was comparable to meropenem except for an increased additional rise in serum creatinine in the plazomicin arm compared to the meropenem arm. This review focuses on the mode of action, antimicrobial activity, pharmacokinetics, clinical indications, and safety profile of this drug. Considerations for formulary addition and its place in therapy are also discussed.